ADHD Rating Scale-IV: School Checklist

DuPaul, George J.; Power, Thomas J.; Anastopoulos, Arthur D.; Reid, Robert

doi:10.1037/t00680-000

Cited by 984 publications

(1,141 citation statements)

References 0 publications

Supporting

Mentioning

1,065

Contrasting

Unclassified

Order By: Relevance

“…(2) an adverse event (AE) profile that was not tolerable; or (3) a daily dose reaching 54 mg, the maximum approved dose of OROS MPH for this age group. In the standardization of the ADHD-RS-IV, scores greater than or equal to the 80th percentile clearly discriminated children with ADHD from their peers given age and gender (DuPaul et al 1998). Scores less than or equal to the 75th percentile were the targeted treatment goal because this was felt to be the range in which children with ADHD would exhibit minimal symptoms and be indistinguishable from their peers without ADHD.…”

Section: Methodsmentioning

confidence: 97%

“…The diagnosis of ADHD was based on semistructured interviews with parents (Kaufman Revised Schedule for Affective Disorders and Schizophrenia for School Age Children: Present and Lifetime Version [K-SADS-PL]) (Kaufman et al 1997). Subjects also were required to have a baseline ADHD Rating Scale-IV (ADHD-RS-IV) score in the 90th percentile or greater relative to the general population of children of the same age and gender (DuPaul et al 1998). Subjects receiving medication to treat their ADHD at the time of study enrollment exhibited an inadequate response to their then-current stimulant dose and completed a washout equivalent to 5 half-lives of the given medication before completing baseline assessments.…”

Section: Study Participantsmentioning

confidence: 99%

See 1 more Smart Citation

Academic, Behavioral, and Cognitive Effects of OROS^® Methylphenidate on Older Children with Attention-Deficit/Hyperactivity Disorder

Wigal

Wigal²,

Schuck³

et al. 2011

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Objective: To assess the effect of Osmotic-Release Oral System (OROS) methylphenidate (MPH) on a variety of measures evaluating academic performance, cognition, and social behavior in children with attention-deficit/hyperactivity disorder (ADHD). Methods: This double-blind, randomized, placebo-controlled, crossover laboratory school study enrolled 78 children aged 9-12 years with ADHD who responded to OROS MPH. After determining individualized OROS MPH dosing (18-54 mg/day), 71 subjects received blinded treatment (OROS MPH or placebo then vice versa) on each of 2 laboratory school days, separated by 1 week. Primary efficacy was measured by Permanent Product Measure of Performance at 4 hours after study drug administration. Results: Treatment with OROS MPH resulted in statistically significant improvement in Permanent Product Measure of Performance and Swanson, Kotkin, Agler, M-Flynn, and Pelham scores, measures of response time, and of working memory compared to placebo. Other measures did not meet all pre-established criteria for significance (maintenance of the overall type I error rate at 5%). Adverse events were consistent with previous reports of stimulant medications used in the management of ADHD. There were no discontinuations due to adverse events, and no serious adverse events or deaths. Conclusions: OROS MPH dosed to reduce core symptoms of ADHD to within the normal range also improved performance on a variety of academic tasks in school-aged children compared to placebo. Adverse effects reported were consistent with prior studies. Clinical Trial Registry Information: Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral and Cognitive Effects of Concerta on Older Children with ADHD, URL: http://clinicaltrials.gov/ct2/ show/NCT00799409, unique identifier: NCT00799409.

show abstract

Section: Methodsmentioning

confidence: 97%

Section: Study Participantsmentioning

confidence: 99%

Academic, Behavioral, and Cognitive Effects of OROS^® Methylphenidate on Older Children with Attention-Deficit/Hyperactivity Disorder

Wigal

Wigal²,

Schuck³

et al. 2011

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Children previously taking stimulant medications completed a 2-week washout period prior to beginning the study. During the initial visit and at each weekly visit, children and their parents met with the clinical staff to discuss medication effects and to complete the ADHD Rating Scale-IV: Home Version (ADHD-RS) (DuPaul et al, 1998), and Stimulant Side Effect Scale (Barkley et al, 1990). In addition, Clinical Global Impression-Severity of Impairment (CGI-S) ratings were completed (Guy, 1976), which ranged from 1 ('no impairment, normal') to 7 ('maximal, profound impairment').…”

Section: Methodsmentioning

confidence: 99%

Dopamine Transporter Genotype and Methylphenidate Dose Response in Children with ADHD

Stein

Waldman

Sarampote

et al. 2005

Neuropsychopharmacol

130

117

View full text Add to dashboard Cite

Stimulant medications, such as methylphenidate (MPH), are the most commonly used, effective treatment for ADHD. MPH acts primarily by inhibiting the dopamine transporter (DAT), a protein responsible for the reuptake of dopamine from the synapse into presynaptic terminals. We sought to evaluate the relationship between DAT1 3 0 -untranslated region (3 0 -UTR) variable number tandem repeats (VNTR) genotypes and dose response to MPH. Children with ADHD (n ¼ 47), ages 5-16 years (mean ¼ 9.02 years), underwent a 4-week, double-blinded, crossover trial with forced weekly dosage changes. Children were genotyped for the DAT1 VNTR and evaluated on placebo and three dosage levels of OROS s MPH. Parents and clinicians who were blind to genotype and medication status rated ADHD symptoms, impairment, and stimulant side effects each week. Children who were homozygous for the less common, 9-repeat DAT1 3 0 -UTR genotype displayed a distinct dose-response curve from that of the other genotype groups, with an absence of typical linear improvement when the dose was increased from 18 mg to 36 and 54 mg. Further research is needed to determine the mechanisms related to poor response in patients with the 9/9-repeat genotype, and to determine if this group responds differentially to alternative treatments.

show abstract

“…The diagnosis of ADHD in adulthood was evaluated with the Structured Clinical Interview for DSM-IV Axis I and II Disorders (SCID-I and SCID-II) and the Conners' Adult ADHD Diagnostic Interview for DSM-IV (CAADID Parts I and II). 46 Severity of ADHD symptoms was evaluated with the long version of the Conners' ADHD Rating Scale (self-report form CAARS-S:L and observer form CAARS-O:L), 47 the ADHD Rating Scale (ADHD-RS), 48 . The diagnosis of ADHD in children was evaluated with the present and lifetime version of the Schedule for Affective Disorders and Schizophrenia for School-age children (K-SADS-PL).…”

Section: Clinical Assessmentmentioning

confidence: 99%

Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB

et al. 2007

View full text Add to dashboard Cite

Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder in which different genetic and environmental susceptibility factors are involved. Several lines of evidence support the view that at least 30% of ADHD patients diagnosed in childhood continue to suffer the disorder during adulthood and that genetic risk factors may play an essential role in the persistence of the disorder throughout lifespan. Genetic, biochemical and pharmacological studies support the idea that the serotonin system participates in the etiology of ADHD. Based on these data, we aimed to analyze single nucleotide polymorphisms across 19 genes involved in the serotoninergic neurotransmission in a clinical sample of 451 ADHD patients (188 adults and 263 children) and 400 controls using a population-based association study. Several significant associations were found after correcting for multiple testing: (1) the DDC gene was strongly associated with both adulthood (P = 0.00053; odds ratio (OR) = 2.17) and childhood ADHD (P = 0.0017; OR = 1.90); (2) the MAOB gene was found specifically associated in the adult ADHD sample (P = 0.0029; OR = 1.90) and (3) the 5HT2A gene showed evidence of association only with the combined ADHD subtype both in adults (P = 0.0036; OR = 1.63) and children (P = 0.0084; OR = 1.49). Our data support the contribution of the serotoninergic system in the genetic predisposition to ADHD, identifying common childhood and adulthood ADHD susceptibility factors, associations that are specific to ADHD subtypes and one variant potentially involved in the continuity of the disorder throughout lifespan.

show abstract

ADHD Rating Scale-IV: School Checklist

Cited by 984 publications

References 0 publications

Academic, Behavioral, and Cognitive Effects of OROS^® Methylphenidate on Older Children with Attention-Deficit/Hyperactivity Disorder

Academic, Behavioral, and Cognitive Effects of OROS^® Methylphenidate on Older Children with Attention-Deficit/Hyperactivity Disorder

Dopamine Transporter Genotype and Methylphenidate Dose Response in Children with ADHD

Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB

Contact Info

Product

Resources

About

ADHD Rating Scale-IV: School Checklist

Cited by 984 publications

References 0 publications

Academic, Behavioral, and Cognitive Effects of OROS® Methylphenidate on Older Children with Attention-Deficit/Hyperactivity Disorder

Academic, Behavioral, and Cognitive Effects of OROS® Methylphenidate on Older Children with Attention-Deficit/Hyperactivity Disorder

Dopamine Transporter Genotype and Methylphenidate Dose Response in Children with ADHD

Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB

Contact Info

Product

Resources

About

Academic, Behavioral, and Cognitive Effects of OROS^® Methylphenidate on Older Children with Attention-Deficit/Hyperactivity Disorder

Academic, Behavioral, and Cognitive Effects of OROS^® Methylphenidate on Older Children with Attention-Deficit/Hyperactivity Disorder